Thomas Cerny

Title: Thomas Cerny: Innovator in Cancer Biomarker Discovery

Introduction

Thomas Cerny is a notable inventor based in St. Gallen, Switzerland. He has made significant contributions to the field of cancer diagnostics, particularly in the discovery of biomarkers for prostate cancer. With a total of 2 patents, his work focuses on improving the accuracy and reliability of cancer detection methods.

Latest Patents

Cerny's latest patents include a method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment. This invention relates to biomarker assays based on protein and peptide biomarkers that exhibit distinct behaviors between healthy and cancerous sample proteomes. The methods involve mass spectrometric measurements and antibody-based assays, such as Enzyme-Linked Immunosorbent Assays (ELISA), to determine the presence of these biomarkers in serum, plasma, or blood samples.

Another significant patent by Cerny outlines a comprehensive method for identifying cancer diagnostic and therapeutic biomarkers. This process includes several steps, such as identifying potential candidate biomarkers based on protein concentrations in tissue samples, verifying these candidates through quantitative mass spectrometric measurements, and validating them using statistical methods. The ultimate goal is to develop reliable biomarker assays for the diagnosis of localized or non-localized prostate cancer.

Career Highlights

Throughout his career, Thomas Cerny has worked with esteemed institutions, including ETH Zurich and Kantonsspital St. Gallen. His experience in these organizations has allowed him to collaborate with leading experts in the field, enhancing his research and innovation capabilities.

Collaborations

Cerny has collaborated with notable colleagues such as Wilhelm Krek and Igor Cima. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Thomas Cerny is a pioneering inventor whose work in cancer biomarker discovery has the potential to revolutionize prostate cancer diagnostics. His innovative methods and collaborations with leading institutions underscore his commitment to improving healthcare outcomes.